PD455 - THE EFFECTS OF VITAMIN D SUPPLEMENTATION ON PATIENTS WITH PREDIABETES AND TYPE 2 DIABETES

PD455

THE EFFECTS OF VITAMIN D SUPPLEMENTATION ON PATIENTS WITH PREDIABETES AND TYPE 2 DIABETES

Y. Tang^1,*, L. Wang¹, Y. Liu¹, Y. He¹

¹National Institute for Nutrition and Health Chinese Center for Disease Control and Prevention, BEIJING, China

Rationale: T2DM and prediabetes are major public health concerns worldwide. Whether vitamin D supplementation can improve glycemic outcomes in these populations remains clinically important but uncertain.

Methods: A systematic review and meta-analysis of 26 RCTs was conducted to assess the effects of vitamin D supplementation in individuals with prediabetes and T2DM. Outcomes included FPG, HbA1c, FINS, 2hPPG, HOMA-IR, and serum 25(OH)D. Pooled MDs with 95% CIs were calculated.Sensitivity analysis and funnel plots were used to assess result robustness and publication bias.

Results: Vitamin D supplementation significantly improved glucose metabolism in both prediabetes and T2DM populations, with stage-specific effects. In prediabetes, supplementation significantly reduced FPG and FINS, with greater benefits observed in individuals with BMI <30 kg/m², daily administration, and lower doses (<2000 IU/day), suggesting a potential role in delaying progression to T2DM. In T2DM, vitamin D supplementation significantly improved FPG and HbA1c, with greater effects observed under daily, high-dose (>4000 IU/day), and longer-duration (>3 months) interventions, independent of glucose-lowering treatment regimens. Serum 25(OH)D levels increased significantly in both populations, while no significant effects were observed for 2hPPG or HOMA-IR. The overall risk of bias was acceptable, no evident publication bias was detected, and the findings for FPG in prediabetes and HbA1c in T2DM were relatively robust.

Image:

Conclusion: Vitamin D supplementation may provide beneficial but stage-specific effects on glucose metabolism in prediabetes and T2DM. Individualized supplementation strategies based on disease stage, BMI, dose, dosing frequency, and intervention duration may help optimize glycemic control and management, while monitoring serum 25(OH)D levels and relevant safety indicators.

Disclosure of Interest: None declared